Ohio Administrative Code
Title 4729:9 - Controlled Substances
Chapter 4729:9-1 - Controlled Substance Schedules
Section 4729:9-1-03 - Schedule III controlled substances
Universal Citation: OH Admin Code 4729:9-1-03
Current through all regulations passed and filed through September 16, 2024
Pursuant to section 3719.41 of the Revised Code, controlled substance schedule III is hereby established, which schedules include the following, subject to amendment pursuant to section 3719.43 or 3719.44 of the Revised Code.
(A) Stimulants
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, their optical isomers, position isomers, or geometric isomers, and salts of these isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) All stimulant compounds, mixtures, and
preparations included in schedule III pursuant to the federal drug abuse
control laws and regulations adopted under those laws;
(2) Benzphetamine;
(3) Chlorphentermine;
(4) Clortermine
(5) Phendimetrazine.
(B) Depressants
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1) Any compound, mixture, or preparation
containing amobarbital, secobarbital, pentobarbital, or any salt of any of
these drugs, and one or more other active medicinal ingredients that are not
listed in any schedule;
(2) Any
suppository dosage form containing amobarbital, secobarbital, pentobarbital, or
any salt of any of these drugs and approved by the food and drug administration
for marketing only as a suppository;
(3) Any substance that contains any quantity
of a derivative of barbituric acid or any salt of a derivative of barbituric
acid;
(4) Chlorhexadol;
(5) Embutramide;
(6) Any dangerous drug containing gamma
hydroxybutyric acid, including its salts, isomers, and salts of isomers, for
which an application is approved under section 505 of the Federal Food, Drug,
and Cosmetic Act (8/20/2019);
(7)
Ketamine, its salts, isomers, and salts of isomers (some other names for
ketamine: (+/-)-2-(2- chlorophenyl)-2-(methylamino)-cyclohexanone);
(8) Lysergic acid;
(9) Lysergic acid amide;
(10) Methyprylon;
(11) Sulfondiethylmethane;
(12) Sulfonethylmethane;
(13) Sulfonmethane;
(14) Tiletamine, zolazepam, or any salt of
tiletamine or zolazepam (some trade or other names for a tiletamine-zolazepam
combination product: Telazol); (some trade or other names for tiletamine:
2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some trade or other names for
zolazepam: 4-(2- fluorophenyl)-6,8- dihydro-1,3,8-trimethylpyrazolo-[3, 4-e]
[1,4]-diazepin-7(1H)-one; flupyrazapon)
;
(15)
Xylazine.
(C) Narcotic antidotes
Nalorphine.
(D) Narcotics-narcotic preparations
Unless specifically excepted under federal drug abuse control laws or unless listed in another schedule, any material, compound, mixture, or preparation that contains any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than 1.8
grams of codeine per one hundred milliliters or not more than ninety milligrams
per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
of opium;
(2) Not more than 1.8
grams of codeine per one hundred milliliters or not more than ninety milligrams
per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;
(3) Not more
than 1.8 grams of dihydrocodeine per one hundred milliliters or not more than
ninety milligrams per dosage unit, with one or more active, nonnarcotic
ingredients in recognized therapeutic amounts;
(4) Not more than three hundred milligrams of
ethylmorphine per one hundred milliliters or not more than fifteen milligrams
per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts;
(5) Not more
than five hundred milligrams of opium per one hundred milliliters or per one
hundred grams or not more than twenty-five milligrams per dosage unit, with one
or more active, nonnarcotic ingredients in recognized therapeutic
amounts;
(6) Not more than fifty
milligrams of morphine per one hundred milliliters or per one hundred grams,
with one or more active, nonnarcotic ingredients in recognized therapeutic
amounts.
(7) Any material,
compound, mixture, or preparation containing any of the following narcotic
drugs or their salts, set forth as follows:
Buprenorphine.
(E) Anabolic steroids
(1) Unless specifically excepted under
federal drug abuse control laws or unless listed in another schedule, any
material, compound, mixture, or preparation that contains any quantity of the
following substances, including their salts, esters, isomers, and salts of
esters and isomers, whenever the existence of these salts, esters, and isomers
is possible within the specific chemical designation.
(2) Anabolic steroids. Except as otherwise
provided in paragraph (E)(1) of this rule, "anabolic steroids" means any drug
or hormonal substance that is chemically and pharmacologically related to
testosterone (other than estrogens, progestins, and corticosteroids) and that
promotes muscle growth. "Anabolic steroids" does not include an anabolic
steroid that is expressly intended for administration through implants to
cattle or other nonhuman species and that has been approved by the United
States secretary of health and human services for that administration, unless a
person prescribes, dispenses, or distributes this type of anabolic steroid for
human use. "Anabolic steroid" includes, but is not limited to, the following:
(a)
3beta,17-dihydroxy-5a-androstane;
(b)
3alpha,17beta-dihydroxy-5a-androstane;
(c) 5alpha-androstan-3,17-dione;
(d) 1-androstenediol
(3beta,17beta-dihydroxy-5a-androst-1-ene);
(e) 1-androstenediol
(3alpha,17beta-dihydroxy-5a-androst-1-ene);
(f) 4-androstenediol
(3beta,17beta-dihydroxy-androst-4-ene);
(g) 5-androstenediol
(3beta,17beta-dihydroxy-androst-5-ene);
(h) 1-androstenedione
([5alpha]-androst-1-en-3,17-dione);
(i) 4-androstenedione
(androst-4-en-3,17-dione);
(j)
5-androstenedione (androst-5-en-3,17-dione);
(k) Bolasterone
(7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
(l) Boldenone
(17beta-hydroxyandrost-1,4-diene-3-one);
(m) Boldione
(androsta-1,4-diene-3,17-dione);
(n) Calusterone
(7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
(o) Clostebol
(4-chloro-17beta-hydroxyandrost-4-en-3-one);
(p) Dehydrochloromethyltestosterone
(4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);
(q) Desoxymethyltestosterone
(17alpha-methyl-5alpha-androst-2-en-17beta-ol) (a.k.a. 'madol');
(r) Delta 1-dihydrotestosterone
(a.k.a.'1-testosterone') (17beta-hydroxy-5alpha-androst-1-en-3-one);
(s) 4-dihydrotestosterone
(17beta-hydroxy-androstan-3-one);
(t) Drostanolone
(17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
(u) Ethylestrenol
(17alpha-ethyl-17beta-hydroxyestr-4-ene);
(v) Fluoxymesterone
(9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);
(w) Formebolone
(2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-dien-3-one);
(x) Furazabol
(17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
(y)
13beta-ethyl-17beta-hydroxygon-4-en-3-one;
(z) 4-hydroxytestosterone
(4,17beta-dihydroxy-androst-4-en-3-one);
(aa) 4-hydroxy-19-nortestosterone
(4,17beta-dihydroxy-estr-4-en-3-one);
(bb) Mestanolone
(17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
(cc) Mesterolone
(1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
(dd) Methandienone
(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);
(ee) Methandriol
(17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);
(ff) Methasterone
(2alpha,17alpha-dimethyl-5alpha-androstan-17beta-ol-3-one);
(gg) Methenolone
(1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
(hh)
17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;
(ii)
17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;
(jj)
17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene;
(kk) 17alpha-methyl-4-hydroxynandrolone
(17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
(ll) Methyldienolone
(17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
(mm) Methyltrienolone
(17alpha-methyl-17beta-hydroxyestra-4,9,11-trien-3-one);
(nn) Methyltestosterone
(17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
(oo) Mibolerone
(7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
(pp)
17alpha-methyl-delta1-dihydrotestosterone
(17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (a.k.a.
'17-alpha-methyl-1-testosterone');
(qq) Nandrolone
(17beta-hydroxyestr-4-en-3-one);
(rr) 19-nor-4-androstenediol (3beta,
17beta-dihydroxyestr-4-ene);
(ss)
19-nor-4-androstenediol (3alpha, 17beta-dihydroxyestr-4-ene);
(tt) 19-nor-5-androstenediol (3beta,
17beta-dihydroxyestr-5-ene);
(uu)
19-nor-5-androstenediol (3alpha, 17beta-dihydroxyestr-5-ene);
(vv) 19-nor-4,9(10)-androstadienedione
(estra-4,9(10)-diene-3,17-dione);
(ww) 19-nor-4-androstenedione
(estr-4-en-3,17-dione);
(xx)
19-nor-5-androstenedione (estr-5-en-3,17-dione);
(yy) Norbolethone (13beta,
17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
(zz) Norclostebol
(4-chloro-17beta-hydroxyestr-4-en-3-one);
(aaa) Norethandrolone
(17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
(bbb) Normethandrolone
(17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
(ccc) Oxandrolone
(17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);
(ddd) Oxymesterone
(17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
(eee) Oxymetholone
(17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan-3-one);
(fff) Prostanozol
(17beta-hydroxy-5alpha-androstano[3,2-c]pyrazole);
(ggg) Stanozolol
(17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);
(hhh) Stenbolone
(17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
(iii) Testolactone
(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);
(jjj) Testosterone
(17beta-hydroxyandrost-4-en-3-one);
(kkk) Tetrahydrogestrinone (13beta,
17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);
(lll) Trenbolone
(17beta-hydroxyestr-4,9,11-trien-3-one);
(mmm) Methandranone;
(nnn) Any salt, ester, isomer, or salt of an
ester or isomer of a drug or hormonal substance described or listed in
paragraph (E)(2) of this rule if the salt, ester, or isomer promotes muscle
growth.
(F) Hallucinogenic substances
Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product (some other names for dronabinol: (6aR-trans)- 6a,7,8,10a-tetrahydro- 6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)- tetrahydrocannabinol).
Effective:
9/28/2023
Five Year Review (FYR) Dates:
3/22/2025
Promulgated Under:
119.03
Statutory Authority: 3719.41, 3719.44, 3719.28, 4729.26
Rule Amplifies: 3719.41
Prior Effective Dates:
09/01/2014, 03/22/2020, 03/29/2023
(Emer.)
Disclaimer: These regulations may not be the most recent version. Ohio may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
